Jazz Pharmaceuticals (JAZZ) PT Raised to $283 at Morgan Stanley
August 11, 2026 9:09 AM
Morgan Stanley analyst Jeffrey Hung raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $283.00 (from $280.00) while maintaining a Overweight rating.
